Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
5,401
archived clinical trials in
Alzheimer Disease

A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's Disease
Study AZ3110866, a Fixed Dose Study of SB-742457 Versus Placebo When Added to Existing Donepezil Treatment in Subjects With Mild-to-moderate Alzheimer's Disease
Status: Enrolling
Updated:  11/3/2017
GSK Investigational Site
mi
from
Austin, TX
A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's Disease
Study AZ3110866, a Fixed Dose Study of SB-742457 Versus Placebo When Added to Existing Donepezil Treatment in Subjects With Mild-to-moderate Alzheimer's Disease
Status: Enrolling
Updated: 11/3/2017
GSK Investigational Site
mi
from
Austin, TX
Click here to add this to my saved trials
A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's Disease
Study AZ3110866, a Fixed Dose Study of SB-742457 Versus Placebo When Added to Existing Donepezil Treatment in Subjects With Mild-to-moderate Alzheimer's Disease
Status: Enrolling
Updated:  11/3/2017
GSK Investigational Site
mi
from
Bennington, VT
A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's Disease
Study AZ3110866, a Fixed Dose Study of SB-742457 Versus Placebo When Added to Existing Donepezil Treatment in Subjects With Mild-to-moderate Alzheimer's Disease
Status: Enrolling
Updated: 11/3/2017
GSK Investigational Site
mi
from
Bennington, VT
Click here to add this to my saved trials
A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's Disease
Study AZ3110866, a Fixed Dose Study of SB-742457 Versus Placebo When Added to Existing Donepezil Treatment in Subjects With Mild-to-moderate Alzheimer's Disease
Status: Enrolling
Updated:  11/3/2017
GSK Investigational Site
mi
from
Ciudad Autonoma de Buenos Aires,
A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's Disease
Study AZ3110866, a Fixed Dose Study of SB-742457 Versus Placebo When Added to Existing Donepezil Treatment in Subjects With Mild-to-moderate Alzheimer's Disease
Status: Enrolling
Updated: 11/3/2017
GSK Investigational Site
mi
from
Ciudad Autonoma de Buenos Aires,
Click here to add this to my saved trials
Cataract Removal and Alzheimer's Disease
Therapeutic Effects of Cataract Removal in Alzheimer's Disease
Status: Enrolling
Updated:  11/7/2017
University Hospitals at Case Medical Center
mi
from
Cleveland, OH
Cataract Removal and Alzheimer's Disease
Therapeutic Effects of Cataract Removal in Alzheimer's Disease
Status: Enrolling
Updated: 11/7/2017
University Hospitals at Case Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Cataract Removal and Alzheimer's Disease
Therapeutic Effects of Cataract Removal in Alzheimer's Disease
Status: Enrolling
Updated:  11/7/2017
MetroHealth Med Ctr
mi
from
Cleveland, OH
Cataract Removal and Alzheimer's Disease
Therapeutic Effects of Cataract Removal in Alzheimer's Disease
Status: Enrolling
Updated: 11/7/2017
MetroHealth Med Ctr
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study of ITI-007 in Healthy Geriatric Volunteers and in Geriatric Patients With Dementia
A Randomized, Double-blind, Placebo-controlled, Multiple Oral Dose Escalation for Safety, Tolerability and Pharmacokinetics of ITI-007 in Healthy Geriatric Volunteers and in Geriatric Patients With Dementia.
Status: Enrolling
Updated:  11/13/2017
Clinical Research Facility
mi
from
Glendale, CA
Study of ITI-007 in Healthy Geriatric Volunteers and in Geriatric Patients With Dementia
A Randomized, Double-blind, Placebo-controlled, Multiple Oral Dose Escalation for Safety, Tolerability and Pharmacokinetics of ITI-007 in Healthy Geriatric Volunteers and in Geriatric Patients With Dementia.
Status: Enrolling
Updated: 11/13/2017
Clinical Research Facility
mi
from
Glendale, CA
Click here to add this to my saved trials
Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells in Patients With Alzheimer's Disease
An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Vascular Fraction (AD-SVF) Cells Delivered Intravenous (IV) and Intranasal in Patients With Alzheimer's Disease
Status: Enrolling
Updated:  11/21/2017
Ageless Regenerative Institute LLC
mi
from
Aventura, FL
Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells in Patients With Alzheimer's Disease
An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Vascular Fraction (AD-SVF) Cells Delivered Intravenous (IV) and Intranasal in Patients With Alzheimer's Disease
Status: Enrolling
Updated: 11/21/2017
Ageless Regenerative Institute LLC
mi
from
Aventura, FL
Click here to add this to my saved trials
CNS and Plasma Amyloid-Beta Kinetics in Alzheimer's Disease
CNS and Plasma Amyloid-Beta Kinetics in Alzheimers's Disease; A Blood Isotope Labeled Amyloid-beta Test for Alzheimer's Disease.
Status: Enrolling
Updated:  12/1/2017
Washington University in St. Louis
mi
from
Saint Louis, MO
CNS and Plasma Amyloid-Beta Kinetics in Alzheimer's Disease
CNS and Plasma Amyloid-Beta Kinetics in Alzheimers's Disease; A Blood Isotope Labeled Amyloid-beta Test for Alzheimer's Disease.
Status: Enrolling
Updated: 12/1/2017
Washington University in St. Louis
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study
Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study: A Coverage With Evidence Development Longitudinal Cohort Study
Status: Enrolling
Updated:  12/6/2017
American College of Radiology Imaging Network
mi
from
Philadelphia, PA
Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study
Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study: A Coverage With Evidence Development Longitudinal Cohort Study
Status: Enrolling
Updated: 12/6/2017
American College of Radiology Imaging Network
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study
Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study: A Coverage With Evidence Development Longitudinal Cohort Study
Status: Enrolling
Updated:  12/6/2017
Https://Www.Ideas-Study.Org/Site-Locator/
mi
from
Philadelphia, PA
Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study
Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study: A Coverage With Evidence Development Longitudinal Cohort Study
Status: Enrolling
Updated: 12/6/2017
Https://Www.Ideas-Study.Org/Site-Locator/
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Disrupted Sleep, Neuroendocrine Status and the Behavioral Symptoms of AD
Disrupted Sleep, Neuroendocrine Status and the Behavioral Symptoms of Alzheimer's Disease (AD)
Status: Enrolling
Updated:  12/8/2017
Johns Hopkins University
mi
from
Baltimore, MD
Disrupted Sleep, Neuroendocrine Status and the Behavioral Symptoms of AD
Disrupted Sleep, Neuroendocrine Status and the Behavioral Symptoms of Alzheimer's Disease (AD)
Status: Enrolling
Updated: 12/8/2017
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
n-3 PUFA for Vascular Cognitive Aging
Omega 3 PUFA for the Vascular Component of Age-related Cognitive Decline
Status: Enrolling
Updated:  12/18/2017
Oregon Health and Science University
mi
from
Portland, OR
n-3 PUFA for Vascular Cognitive Aging
Omega 3 PUFA for the Vascular Component of Age-related Cognitive Decline
Status: Enrolling
Updated: 12/18/2017
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers
Randomised, Parallel-group, Double-blind Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Age-comparable Healthy Volunteers
Status: Enrolling
Updated:  12/18/2017
Altman Clinical and Translational Research Institute
mi
from
La Jolla, CA
Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers
Randomised, Parallel-group, Double-blind Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Age-comparable Healthy Volunteers
Status: Enrolling
Updated: 12/18/2017
Altman Clinical and Translational Research Institute
mi
from
La Jolla, CA
Click here to add this to my saved trials
Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers
Randomised, Parallel-group, Double-blind Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Age-comparable Healthy Volunteers
Status: Enrolling
Updated:  12/18/2017
Memory Enhancement Center of America, Inc.
mi
from
Eatontown, NJ
Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers
Randomised, Parallel-group, Double-blind Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Age-comparable Healthy Volunteers
Status: Enrolling
Updated: 12/18/2017
Memory Enhancement Center of America, Inc.
mi
from
Eatontown, NJ
Click here to add this to my saved trials
Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers
Randomised, Parallel-group, Double-blind Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Age-comparable Healthy Volunteers
Status: Enrolling
Updated:  12/18/2017
Community Clinical Research
mi
from
Austin, TX
Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers
Randomised, Parallel-group, Double-blind Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Age-comparable Healthy Volunteers
Status: Enrolling
Updated: 12/18/2017
Community Clinical Research
mi
from
Austin, TX
Click here to add this to my saved trials
A Study of LY3002813 in Participants With Alzheimer's Disease
A Single-Dose and Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3002813 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/21/2017
Collaborative Neuroscience Network - CNS
mi
from
Long Beach, CA
A Study of LY3002813 in Participants With Alzheimer's Disease
A Single-Dose and Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3002813 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/21/2017
Collaborative Neuroscience Network - CNS
mi
from
Long Beach, CA
Click here to add this to my saved trials
A Study of LY3002813 in Participants With Alzheimer's Disease
A Single-Dose and Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3002813 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/21/2017
Compass Research LLC
mi
from
Orlando, FL
A Study of LY3002813 in Participants With Alzheimer's Disease
A Single-Dose and Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3002813 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/21/2017
Compass Research LLC
mi
from
Orlando, FL
Click here to add this to my saved trials
A Study of LY3002813 in Participants With Alzheimer's Disease
A Single-Dose and Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3002813 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/21/2017
Atlanta Center for Medical Research
mi
from
Atlanta, GA
A Study of LY3002813 in Participants With Alzheimer's Disease
A Single-Dose and Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3002813 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/21/2017
Atlanta Center for Medical Research
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study of LY3002813 in Participants With Alzheimer's Disease
A Single-Dose and Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3002813 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/21/2017
Prahealthsciences
mi
from
Salt Lake City, UT
A Study of LY3002813 in Participants With Alzheimer's Disease
A Single-Dose and Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3002813 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/21/2017
Prahealthsciences
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study of LY3002813 in Participants With Alzheimer's Disease
A Single-Dose and Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3002813 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/21/2017
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
mi
from
Sumida-Ku,
A Study of LY3002813 in Participants With Alzheimer's Disease
A Single-Dose and Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3002813 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/21/2017
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
mi
from
Sumida-Ku,
Click here to add this to my saved trials
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia
A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia
Status: Enrolling
Updated:  12/22/2017
US101
mi
from
Phoenix, AZ
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia
A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia
Status: Enrolling
Updated: 12/22/2017
US101
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia
A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia
Status: Enrolling
Updated:  12/22/2017
US102
mi
from
Ann Arbor, MI
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia
A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia
Status: Enrolling
Updated: 12/22/2017
US102
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia
A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia
Status: Enrolling
Updated:  12/22/2017
US108
mi
from
Pensacola, FL
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia
A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia
Status: Enrolling
Updated: 12/22/2017
US108
mi
from
Pensacola, FL
Click here to add this to my saved trials
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia
A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia
Status: Enrolling
Updated:  12/22/2017
US106
mi
from
Columbus, GA
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia
A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia
Status: Enrolling
Updated: 12/22/2017
US106
mi
from
Columbus, GA
Click here to add this to my saved trials
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia
A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia
Status: Enrolling
Updated:  12/22/2017
US107
mi
from
Indianapolis, IN
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia
A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia
Status: Enrolling
Updated: 12/22/2017
US107
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia
A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia
Status: Enrolling
Updated:  12/22/2017
US118
mi
from
Simi Valley, CA
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia
A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia
Status: Enrolling
Updated: 12/22/2017
US118
mi
from
Simi Valley, CA
Click here to add this to my saved trials
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia
A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia
Status: Enrolling
Updated:  12/22/2017
US117
mi
from
Temecula, CA
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia
A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia
Status: Enrolling
Updated: 12/22/2017
US117
mi
from
Temecula, CA
Click here to add this to my saved trials
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia
A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia
Status: Enrolling
Updated:  12/22/2017
US115
mi
from
Boca Raton, FL
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia
A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia
Status: Enrolling
Updated: 12/22/2017
US115
mi
from
Boca Raton, FL
Click here to add this to my saved trials
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia
A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia
Status: Enrolling
Updated:  12/22/2017
US109
mi
from
Hallandale Beach, FL
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia
A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia
Status: Enrolling
Updated: 12/22/2017
US109
mi
from
Hallandale Beach, FL
Click here to add this to my saved trials
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia
A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia
Status: Enrolling
Updated:  12/22/2017
US116
mi
from
Miami, FL
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia
A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia
Status: Enrolling
Updated: 12/22/2017
US116
mi
from
Miami, FL
Click here to add this to my saved trials
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia
A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia
Status: Enrolling
Updated:  12/22/2017
US111
mi
from
Columbus, OH
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia
A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia
Status: Enrolling
Updated: 12/22/2017
US111
mi
from
Columbus, OH
Click here to add this to my saved trials
TAU PET Imaging in Northern Manhattan Study of Metabolism and Mind
TAU PET Imaging in Northern Manhattan Study of Metabolism and Mind
Status: Enrolling
Updated:  12/27/2017
Columbia University Medical Center
mi
from
New York, NY
TAU PET Imaging in Northern Manhattan Study of Metabolism and Mind
TAU PET Imaging in Northern Manhattan Study of Metabolism and Mind
Status: Enrolling
Updated: 12/27/2017
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Modafinil Treatment for Sleep/Wake Disturbances in Older Adults
Modafinil Treatment for Sleep/Wake Disturbances in Older Adults
Status: Enrolling
Updated:  1/3/2018
VA Palo Alto Health Care System
mi
from
Palo Alto, CA
Modafinil Treatment for Sleep/Wake Disturbances in Older Adults
Modafinil Treatment for Sleep/Wake Disturbances in Older Adults
Status: Enrolling
Updated: 1/3/2018
VA Palo Alto Health Care System
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Cognitive and Functional Connectivity Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease
Cognitive and Functional Connectivity Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease
Status: Enrolling
Updated:  1/3/2018
Research Imaging Institute, The University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Cognitive and Functional Connectivity Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease
Cognitive and Functional Connectivity Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease
Status: Enrolling
Updated: 1/3/2018
Research Imaging Institute, The University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
Venlafaxine for Depression in Alzheimer's Disease (DIADs-3)
Venlafaxine for Depression in Alzheimer's Disease
Status: Enrolling
Updated:  1/4/2018
Johns Hopkins Bayview
mi
from
Baltimore, MD
Venlafaxine for Depression in Alzheimer's Disease (DIADs-3)
Venlafaxine for Depression in Alzheimer's Disease
Status: Enrolling
Updated: 1/4/2018
Johns Hopkins Bayview
mi
from
Baltimore, MD
Click here to add this to my saved trials
Venlafaxine for Depression in Alzheimer's Disease (DIADs-3)
Venlafaxine for Depression in Alzheimer's Disease
Status: Enrolling
Updated:  1/4/2018
Reading Hospital
mi
from
West Reading, PA
Venlafaxine for Depression in Alzheimer's Disease (DIADs-3)
Venlafaxine for Depression in Alzheimer's Disease
Status: Enrolling
Updated: 1/4/2018
Reading Hospital
mi
from
West Reading, PA
Click here to add this to my saved trials
Trial of Carvedilol in Alzheimer's Disease
Pilot Trial of Carvedilol in Alzheimer's Disease
Status: Enrolling
Updated:  1/8/2018
Johns Hopkins School of Medicine Bayview Campus
mi
from
Baltimore, MD
Trial of Carvedilol in Alzheimer's Disease
Pilot Trial of Carvedilol in Alzheimer's Disease
Status: Enrolling
Updated: 1/8/2018
Johns Hopkins School of Medicine Bayview Campus
mi
from
Baltimore, MD
Click here to add this to my saved trials
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.
Status: Enrolling
Updated:  1/8/2018
Clinical Research Facility
mi
from
Phoenix, AZ
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.
Status: Enrolling
Updated: 1/8/2018
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.
Status: Enrolling
Updated:  1/8/2018
Clinical Research Facility
mi
from
Sun City, AZ
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.
Status: Enrolling
Updated: 1/8/2018
Clinical Research Facility
mi
from
Sun City, AZ
Click here to add this to my saved trials
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.
Status: Enrolling
Updated:  1/8/2018
Clinical Research Facility
mi
from
Fresno, CA
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.
Status: Enrolling
Updated: 1/8/2018
Clinical Research Facility
mi
from
Fresno, CA
Click here to add this to my saved trials
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.
Status: Enrolling
Updated:  1/8/2018
Clinical Research Facility
mi
from
Fullerton, CA
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.
Status: Enrolling
Updated: 1/8/2018
Clinical Research Facility
mi
from
Fullerton, CA
Click here to add this to my saved trials
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.
Status: Enrolling
Updated:  1/8/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.
Status: Enrolling
Updated: 1/8/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.
Status: Enrolling
Updated:  1/8/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.
Status: Enrolling
Updated: 1/8/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.
Status: Enrolling
Updated:  1/8/2018
Clinical Research Facility
mi
from
San Diego, CA
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.
Status: Enrolling
Updated: 1/8/2018
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.
Status: Enrolling
Updated:  1/8/2018
Clinical Research Facility
mi
from
San Francisco, CA
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.
Status: Enrolling
Updated: 1/8/2018
Clinical Research Facility
mi
from
San Francisco, CA
Click here to add this to my saved trials
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.
Status: Enrolling
Updated:  1/8/2018
Clinical Research Facility
mi
from
Sherman Oaks, CA
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.
Status: Enrolling
Updated: 1/8/2018
Clinical Research Facility
mi
from
Sherman Oaks, CA
Click here to add this to my saved trials
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.
Status: Enrolling
Updated:  1/8/2018
Clinical Research Facility
mi
from
Temecula, CA
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.
Status: Enrolling
Updated: 1/8/2018
Clinical Research Facility
mi
from
Temecula, CA
Click here to add this to my saved trials
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.
Status: Enrolling
Updated:  1/8/2018
Clinical Research Facility
mi
from
Boynton Beach, FL
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.
Status: Enrolling
Updated: 1/8/2018
Clinical Research Facility
mi
from
Boynton Beach, FL
Click here to add this to my saved trials
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.
Status: Enrolling
Updated:  1/8/2018
Clinical Research Facility
mi
from
Deerfield Beach, FL
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.
Status: Enrolling
Updated: 1/8/2018
Clinical Research Facility
mi
from
Deerfield Beach, FL
Click here to add this to my saved trials
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.
Status: Enrolling
Updated:  1/8/2018
Clinical Research Facility
mi
from
Hialeah, FL
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.
Status: Enrolling
Updated: 1/8/2018
Clinical Research Facility
mi
from
Hialeah, FL
Click here to add this to my saved trials